Skip to content
All Podcasts – Lifestyle
Author:
Zydus Therapeutics, Inc.
Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC
October 12, 2026